Abstract

Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.

Keywords

IvermectinVirologyVero cellSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DrugMedicineClinical trialOutbreakBiologyIn vitroVirusCoronavirus disease 2019 (COVID-19)PharmacologyBioinformaticsInfectious disease (medical specialty)Internal medicineVeterinary medicine

Affiliated Institutions

Related Publications

Publication Info

Year
2020
Type
article
Volume
178
Pages
104787-104787
Citations
2229
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

2229
OpenAlex

Cite This

Leon Caly, Julian Druce, Mike Catton et al. (2020). The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research , 178 , 104787-104787. https://doi.org/10.1016/j.antiviral.2020.104787

Identifiers

DOI
10.1016/j.antiviral.2020.104787